Catalog4 refs
Rusfertide
OtherResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Circulation
Overview
A synthetic hepcidin mimetic that controls iron availability by degrading the iron exporter ferroportin, limiting iron entry into the bloodstream. Being developed to manage polycythemia vera (PV), a blood cancer that causes overproduction of red blood cells, by starving the overactive marrow of iron. Reduces the need for repeated phlebotomy. Currently under FDA priority review with NDA submitted January 2026, holding Breakthrough Therapy, Orphan Drug, Fast Track, and Priority Review designations. Phase 3 VERIFY trial met primary and all key secondary endpoints.
Primary Uses
Polycythemia vera management
Reducing phlebotomy frequency
Hematocrit control
TRT-induced erythrocytosis (potential application)
Protocol Reference
Dose
40-80 mg weekly (maintenance); trial range 10-120 mg weekly
Frequency
Once weekly
Route
Subcutaneous injection
Evidence
Phase 3 clinical trials complete; NDA submitted under FDA Priority Review with Breakthrough Therapy designation
Research References· 1
Research Models
Human
Also in Other